Category 4

Umbilical-Cord Tissue, Wharton’s Jelly, and Cord Blood

9 topics planned. Each topic is published as a Professional and Patient edition only after explicit author approval.

4.1Umbilical-cord anatomy
In review
1. · Amnion
2. · Wharton’s jelly
3. · Umbilical arteries
4. · Umbilical vein
5. · Perivascular regions
6. · Subamniotic regions
4.2Cord blood versus cord tissue
In review
1. · Hematopoietic progenitor cells
2. · Mesenchymal stromal cells
3. · Cell composition
4. · Established uses
5. · Investigational uses
6. · Common public confusion
4.3Sources of cord-derived MSCs
In review
1. · Whole-cord explants
2. · Wharton’s jelly
3. · Perivascular tissue
4. · Cord lining
5. · Vascular tissue
6. · Source-dependent variability
4.4Donation and procurement
In review
1. · Maternal consent
2. · Donor medical history
3. · Infectious-disease screening
4. · Birth and delivery variables
5. · Collection technique
6. · Transport conditions
7. · Processing timelines
4.5Isolation methods
In review
1. · Explant migration
2. · Enzymatic digestion
3. · Mechanical dissociation
4. · Cell selection
5. · Initial plating
6. · Colony expansion
4.6Proposed advantages
In review
1. · Noninvasive collection
2. · Rapid proliferation
3. · Early developmental age
4. · Allogeneic manufacturing potential
5. · Secretory activity
6. · Immunomodulatory properties
4.7Limitations and uncertainties
In review
1. · Donor heterogeneity
2. · Tissue-region variability
3. · Culture adaptation
4. · Senescence
5. · Immune recognition
6. · Thrombogenic potential
7. · Lack of product equivalence
4.8Cord-blood banking
In review
1. · Public banking
2. · Private banking
3. · Collection standards
4. · HLA typing
5. · Cell-dose requirements
6. · Storage
7. · Release testing
8. · Realistic probability of use
4.9Marketing terminology requiring scrutiny
In review
1. · “Umbilical-cord stem cells”
2. · “Wharton’s-jelly stem cells”
3. · “Birth-tissue products”
4. · “Young cells”
5. · “Immune privileged”
6. · “FDA registered”
7. · “Clinical grade”